SCHEMBL29453654

SCHEMBL29453654

N#CC1(Cc2cc(F)ccc2F)CCN(C(=O)c2cccnc2-c2ccncc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP46A1 Q9Y6A2 7/20 0.54
▸ CYP2C9 P11712 4/20 0.54
▸ CYP3A4 P08684 4/20 0.54
▸ CYP2C19 P33261 3/20 0.54
▸ CYP2C8 P10632 1/20 0.54
▸ ALDH1A1 P00352 7/20 0.42
▸ KDM4E B2RXH2 1/20 0.39
▸ HTR2A P28223 2/20 0.39
▸ HTR2C P28335 2/20 0.39
▸ KCNH2 Q12809 1/20 0.39
▸ HTR1A P08908 1/20 0.38
▸ DRD2 P14416 1/20 0.38
▸ ADRA1A P35348 1/20 0.38
▸ CYP1A2 P05177 2/20 0.38
▸ CYP2D6 P10635 2/20 0.38
▸ TSHR P16473 2/20 0.38
▸ HIF1A Q16665 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22719224 1.00 CYP46A1 (0.54) CYP46A1CYP2C9CYP3A4CYP2C19CYP2C8
SCHEMBL29453683 0.93 CYP46A1 (0.54) CYP46A1CYP2C9CYP3A4CYP2C19CYP2C8
SCHEMBL22719246 0.93 CYP46A1 (0.54) CYP46A1CYP2C9CYP3A4CYP2C19CYP2C8
SCHEMBL22719460 0.90 CYP46A1 (0.59) CYP46A1CYP2C9CYP3A4CYP2C19CYP2C8
SCHEMBL29453711 0.90 CYP46A1 (0.59) CYP46A1CYP2C9CYP3A4CYP2C19CYP2C8
SCHEMBL22719129 0.90 CYP46A1 (0.51) CYP46A1CYP2C9CYP3A4CYP2C19CYP2C8
SCHEMBL29453737 0.90 CYP46A1 (0.51) CYP46A1CYP2C9CYP3A4CYP2C19CYP2C8
SCHEMBL22719375 0.89 CYP46A1 (0.56) CYP46A1CYP2C9CYP3A4CYP2C19CYP2C8
SCHEMBL29453706 0.89 CYP46A1 (0.56) CYP46A1CYP2C9CYP3A4CYP2C19CYP2C8
SCHEMBL22719307 0.88 CYP46A1 (0.56) CYP46A1CYP2C9CYP3A4CYP2C19CYP2C8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220332699-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USE SAGE THERAPEUTICS, INC. 2022-10-20 — — US disclosed
EP-3976186-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Sage Therapeutics, Inc. (US) 2022-04-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332699-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USE CYP46A1, CYP26A1, CYP21A2 CYP46A1 1/4885CYP2C9 38/4885CYP3A4 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback